341 related articles for article (PubMed ID: 22104247)
1. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
7. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
8. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
9. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
[TBL] [Abstract][Full Text] [Related]
10. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
13. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
[TBL] [Abstract][Full Text] [Related]
14. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
[TBL] [Abstract][Full Text] [Related]
15. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
[TBL] [Abstract][Full Text] [Related]
16. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
[TBL] [Abstract][Full Text] [Related]
17. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
[TBL] [Abstract][Full Text] [Related]
18. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
19. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
20. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
